I lost 6st with fat jabs & now have abs at 42 – the exact diet I follow not to put any weight back on
A MUM has revealed how she lost 6st using weight loss jabs after hitting a size 18.
Ellen Ogley, 42, weighed 16st 12lbs at her heaviest and said comfort eating was the primary cause of her rapid weight gain.
3
3
3
Now, the mum-of-three has abs after completely changing her relationship with food.
She first lost three stone naturally but on an "unsustainable diet" so she could get a "quick fix" tummy tuck but was still unhappy with her body.
Ellen then decided to try Mounjaro and immediately found it helped with her "food noise" and stopped her from constantly raiding the snack cupboard.
Now the mum has kept between a healthy 10st to 10st 3lb and a size six for eight months.
She says the one thing she's done that's helped her maintain her weight is swap two-weekly takeaways and binge drinking weekends for 'fakeaways' and weight training and now feels "amazing".
Ellen, a nursery manager, from Ilkley, Yorkshire, said: "I wanted to make sure I wasn't reliant on Mounjaro.
"I used this as a tool. I've done so much work on damage limitation.
"I want to give others hope they can keep it off. I feel incredible."
Ellen started "comfort eating" and piled on the weight in a period of sickness - before she was then diagnosed with cervical and ovarian cancer.
She said: "I had blow outs and would have takeaways and binge drinking - it was a coping mechanism.
"I'd have two to three takeaways a week. My drinking was excessive.
"My husband and I would have three bottles of wine between us - it helped numb everything."
Ellen had to have a hysterectomy and was told she was at a higher risk due to her BMI - which was 36.5 at her biggest.
She said: "I said to myself 'if I come out the other side I will try and take control of my health '."
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
After she got the all clear Ellen decided to lose weight in September 2023 but wanted a "quick fix".
She said: "I was looking for an easy way out. I went to see a surgeon for a tummy tuck.
"But I needed to lose three stone in order to have a tummy tuck and liposuction to get skinny."
Ellen started intermittent fasting and restricted her diet to get down to 13st 10lbs.
She said: "I was doing it in not a very healthy way.
"I was almost starving myself. It was not sustainable."
Ellen went for her £10k tummy tuck in February 2024 and was happy with her results but had hoped the surgery would help shift more of her weight.
She said: "I only lost 4lbs more after the tummy tuck.
"I was devastated.
"I became obsessed with my body - pulling at it, I had huge hang ups over my arms."
Ellen decided to give weight loss medication a go and started Mounjaro in May 2024 - coupling it with cardio exercise.
She said: "I thought it was going to be another diet trend but the food noises got switched off.
I got trolled - they called me Skeletor, I was being told I looked like a 60-year-old.
Ellen Ogley
"Before I would raid the cupboard when my husband took his daughter to gymnastics.
"As soon as I went on I realised 'I've not touched the snack cupboard'.
"I started making better lifestyle choices."
Ellen was on the jab for just 22 weeks - weaning herself off slowly - but started become obsessed with getting as "skinny as possible".
She said: "I lost my focus. I got trolled - they called me Skeletor, I was being told I looked like a 60-year-old."
When her husband, Phil Ogley, 53, a surveyor, told her she looked ill she had a wake up call and refocused - taking up weight training.
Now she feels "healthy and strong" and has maintained her weight loss without micro-dosing Mounjaro.
She said: "I've been learning how to fuel my body.
"I have hacks in place - if I'm craving sweets I have Greek yoghurt, berries and granola.
"I still have takeaways but I exercise portion control.
"We make chicken kebabs as fakeaways instead of ordering them as takeaways.
"I have abs at 42 - it blows my mind."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
33 minutes ago
- The Independent
What do we really know about the long-term use of Mounjaro and Ozempic?
The headlines a few weeks ago were as sensational as they were unsettling. ' Ozempic may stop the pill working properly,' this newspaper reported after the Medicines and Healthcare Products Regulatory Agency (MHRA) issued a warning: pill users should double up on contraception while using the jabs and avoid them altogether during pregnancy or breastfeeding. The British Menopause Society also added that women on HRT taking the drugs might fail to absorb progesterone pills, which could increase the risk of womb cancer. Meanwhile, other reports warned that the injections many are using for weight loss, like Wegovy and Mounjaro, might also carry a hidden risk of kidney cancer. And this month, the European Medicines Agency cautioned that semaglutide could double the risk of a rare sight-loss condition called non-arteritic anterior ischemic optic neuropathy (NAION). These headlines would be alarming even if the drugs were rarely used. But these so-called weight-loss jabs have become so popular that even their manufacturers didn't anticipate the demand - and from this week, GPs are allowed to offer Mounjaro to obese individuals who also suffer from a range of other health complications. As of March 2025, market intelligence company IQVIA estimated that around 1.5 million people in the UK were using weight-loss treatments. With limited NHS availability, roughly 80 per cent of these are purchased privately online and have made the pharma companies that make them some of the most valuable firms in Europe. But with no real long-term studies, do we really know how safe these drugs are? While they will have been thoroughly tested before hitting the market, have manufacturers really considered how people are using them? What do we really know about their long-term effects? Is this truly a medical breakthrough – or just another chapter in the troubled history of slimming pills? A crisis in need of solutions There's no denying that obesity is a public health emergency. Nearly three-quarters of people aged 45 to 74 in the UK are now overweight, up from just over half in 1993. Obesity is linked to conditions such as type 2 diabetes, heart disease, joint problems, infertility, and around 30 types of cancer. It's estimated to cost the NHS £6.5bn a year. Given this, the search for a safe, effective obesity drug has long been seen as medicine's holy grail. But past attempts have often ended in disaster, either due to limited results or serious safety issues. The troubled history of slimming drugs Weight-loss drugs have historically come with significant risks. One of the earliest, 2,4-dinitrophenol, was initially used as an explosive in the First World War. It worked by increasing metabolism, causing the body to burn calories as heat. As hemlines rose in the 1920s, flappers flocked to it, but it turned out that the wrong dose could literally cook users from the inside. Horrific deaths meant the drug was banned in 1938. Later came amphetamine-based drugs, widely used in the Fifties and Sixties until their links to addiction and cardiovascular issues led to bans. More recently, sibutramine (Reductil) and rimonabant (Acomplia) were withdrawn after being linked to heart attacks, strokes, and psychiatric effects. By the time Acomplia was suspended in 2008, four trial participants had died by suicide. Enter: GLP-1 agonists. These new-generation drugs, which include semaglutide and tirzepatide, were the first to mimic our own natural appetite-regulating hormones. The first to hit the market was exenatide – a drug to treat type 2 diabetes – in 2005. Ozempic was then approved in 2017 and Mounjaro in 2023. Clinical trials showed unprecedented weight loss of up to 26 per cent of body weight in some cases, on par with bariatric surgery – and seemingly without the deadly side effects of their predecessors. So, why are these drugs different? 'Most previous drugs targeted the brain, which is where hunger lives,' explains Professor Giles Yeo, a molecular neuroendocrinologist at Cambridge University. 'But that led to serious side effects. These newer drugs are modified, longer-lasting versions of natural hormones – they're designed to go to the right brain regions naturally and for our body to respond to them in the same way they do to our own hormones.' Miracle or minefield? Despite their success, the rapid rise in use has triggered concern. Many users now access these jabs through private online clinics with minimal oversight. Some even acquire illegal 'compounded' medications from beauticians. Social media is flooded with user reviews, micro-dosing tips, and 'before-and-after' photos. But this week, a spokesperson for Novo Nordisk, which markets Ozempic and Wegovy, told the Daily Mail that practices like microdosing weren't recommended. 'The approved doses are the only dose strengths that have been studied and are licensed to use,' they warned. Similarly, the Royal Pharmaceutical Society has warned that without proper supervision, users face risks including dehydration, gallstones, malnutrition, and muscle loss. What do we know about long-term safety? Yeo is optimistic: 'Regulatory bodies like the FDA and EMA are very rigorous. These drugs are approved globally, and they wouldn't be if they were deemed unsafe.' Professor Carel le Roux, a metabolic medicine expert at Ulster University, adds that all approved drugs – not just weight-loss drugs – must be studied for at least 52 weeks. This is because, he says, 'If we haven't seen major issues by a year, we're unlikely to. And this is based on the regulators' experience of tens of thousands of previous studies.' However, less obvious side effects often appear only after widespread use. Le Roux insists that the new findings that have dominated the headlines in the last few weeks are typical of standard 'post-market surveillance' by which pharma companies and regulators continue to collect data. 'Yes, things can emerge,' he says. 'But we've used this class of drugs for 20 years, mostly in people who were sicker than current users. The data is incredibly reassuring.' Le Roux also points out that in trials, participants on these medications had fewer serious adverse events than those on placebo. 'That's because obesity and diabetes are so harmful themselves. There comes a point when it's unethical not to license a drug that can make people healthier.' Untangling the risks Some risks are still being studied. The kidney cancer alert came from a study of 43,000 people on GLP-1 drugs versus 43,000 controls. There were 83 cases in the treatment group compared to 58 in the control group – a slight absolute increase and not necessarily a clear causal link. Conversely, other trials show strong kidney protection. The FLOW trial (2019–2023) followed over 3,500 patients and found a 24 per cent lower risk of kidney failure and a 50 per cent reduction in death from kidney disease among semaglutide users. The findings were so conclusive that the trial ended early in order to offer treatment to the placebo group. Le Roux remains confident: 'We've shown these drugs can reduce heart attacks by up to 25 per cent and cut the risk of developing diabetes in people at risk by 80-90 per cent. Yes, eye issues have emerged, but this particular condition is only seen in people with diabetes, and the risk is around 1 in 10,000.' Yeo also points out that in fact, 'type 2 diabetes is the leading cause of blindness in adults'. So, what about the contraceptive and HRT concerns? Le Roux says vomiting, a known side effect of the drugs, is likely to be to blame rather than the drug blocking absorption per se. 'Anything swallowed will eventually be absorbed – unless it's thrown up.' To reduce nausea while on these drugs, he advises sticking with lower doses, even if that slows weight loss. If vomiting continues to be a problem, switching to non-oral forms of HRT, such as patches, or using condoms or a coil should eliminate the issue. Osteoporosis and other risks Others have expressed concerns about the effect of weight-loss injections on muscles and bones. US singer Avery, who took Ozempic for a year, despite having an eating disorder, recently tearfully revealed she had been diagnosed with osteoporosis. She admitted that she did not get the drug from a doctor. So how common is her experience? A review published last year showed that between 15 and 40 per cent of weight loss with semaglutide could be lean tissue. Yeo says that it's something users should be aware of. 'Anyone losing weight by any means will always lose lean tissue – which includes water, muscle and bone – alongside fat.' However, he says there is no evidence this far that weight loss injections contribute independently to osteoporosis.' Yeo says the best way to mitigate bone loss is with exercise, which studies show can preserve muscle and bone density when taken with these drugs. A protein-rich diet also helps maintain muscle. Reviews have also shown that after weight loss, even though they lost lean tissue, people tended to end up with a higher proportion of lean mass compared to fat and that this muscle could be 'better quality' with stronger muscle fibres. However, in older people with fewer reserves, losing too much weight and muscle, which is harder to rebuild as we age, can be risky. The problem of dependency These drugs don't cure obesity – they manage it. Stop the injections and your appetite returns. One study found that patients regained two-thirds of the weight they had lost within a year of stopping treatment. This raises challenging questions. 'One of the most important questions we ask patients now is, 'Are you willing to take this medication for life?'' says Le Roux. And of course, this comes at a cost, whether it's private consumption (roughly £250 a month) or the NHS, which will have to consider covering lifetime prescriptions. And with the huge sums involved, how do we protect against black-market misuse? The next generation: hope or hype? Current drugs target only one or two appetite-regulating gut hormones. However, as Yeo explains, around 20 gut hormones influence satiety. Next-generation treatments may combine more hormones, allowing lower doses and potentially fewer side effects, such as vomiting. 'These could reduce digestive side effects to zero,' says Yeo. Some new generation weight-loss medications are even being designed to protect muscle and bone mass by activating pathways that mimic the effects of exercise. Yeo says that future, cheap pill forms of the drugs may also prove the secret to lifelong maintenance. With the World Health Organisation announcing in May that it plans to endorse anti-obesity drugs for adult treatment, access may expand globally which could be a medical turning point. But they're not for everybody... Few in medicine doubt that GLP-1 drugs mark a breakthrough. But they are not a one-size-fits-all solution. Around 15 per cent of patients don't respond. And there's growing concern that access remains limited to those who can afford private prescriptions, while NHS patients face restrictions. Many people take them without exercising or improving their diet, which is essential to preserve strong muscles and bones in the future. However, Yeo believes that change is on the way. 'In seven years, Ozempic's patent expires. I predict the cost will fall from £200 to maybe £10 a month. When that happens, the NHS will be able to provide it widely – with proper supervision. These powerful drugs are designed to be used for health reasons, not as a cosmetic tool. They are designed to help people with obesity. If they are taken by skinny people, that's when side effects rocket and the risk vs benefit ratio changes. We need to keep them out of the wrong hands.' Drugs like semaglutide offer a new weapon in the battle against obesity – a condition that has proven difficult to treat for decades and costs the NHS millions in comorbid conditions, which can range from type 2 diabetes, cancer, cardiovascular disease, osteoarthritis and even depression. But they aren't magic bullets. They come with risks, limitations, and hard decisions about long-term use. Appropriately used, with medical oversight and realistic expectations, they can be life-changing. But the real test isn't just in the weight lost this year – it's what happens over the next decade. We should welcome them, but with cautious optimism and our eyes wide open.
BBC News
an hour ago
- BBC News
Maternity services review welcomed by bereaved Leeds parents
Parents who raised concerns about maternity care in Leeds have welcomed news it will be included in a national Secretary Wes Streeting announced the "rapid" inquiry on Monday, focused on the worst-performing maternity and neonatal services in the Kaur and Mandip Singh Matharoo believe their daughter Asees, who was stillborn in 2024, would have survived had they received better care at Leeds General Infirmary (LGI). Ms Kaur said: "Something needs to be done – multiple governments have just let it slide for so many years." Prof Phil Wood, Chief Executive at Leeds Teaching Hospitals NHS Trust, said he would welcome any investigation and would "fully support its focus on improving maternity safety".When Ms Kaur was 32 weeks pregnant, she visited LGI's maternity unit twice in 24 hours, each time telling staff she had ligament pain in her torso. She was sent home both times - but later underwent emergency surgery and a massive blood clot was found, exactly where she had described being in pair believe Asees would have survived if Ms Kaur had not been sent home earlier. On Monday it was confirmed that Leeds Teaching Hospitals (LTH), along with University Hospitals Sussex, would be among the trusts included in the investigation. "We do welcome the fact that there will be an inquiry done nationally," she said."We still do think that there needs to be a closer eye put on Leeds, so we welcome that [Streeting] says he will look at Leeds more specifically."LTH NHS Trust includes LGI and St James' University hospitals had their maternity services downgraded from "good" to "inadequate" by the Care Quality Commission (CQC) last week. Concerns from staff and patients around quality of care and staffing levels led to unannounced inspections at the ratings were changed because their failings posed "a significant risk" to women and babies, according to the CQC. Fiona Winser-Ramm and Dan Ramm set up an online group for bereaved parents after the death of daughter, Aliona Grace, at LGI in died 27 minutes after she was born, with an inquest finding a "number of gross failures of the most basic nature that directly contributed" to her Winser-Ramm said they welcomed the review and the "continuing conversation around the maternity services here in Leeds".However, they both called for an independent inquiry to be held into services at LTH. Mr Ramm said: "We are resolute in continuing to call for that inquiry and today is essentially another day in that process."The big concern is that this will not go far enough, and that essentially after an initial rapid review we will be stranded in that limbo with no answers about culture and management and the problems that have been allowed to perpetuate in LTH for five plus years." The investigation will consist of two parts. The first will urgently investigate up to 10 of the most concerning maternity and neonatal units, to give affected families answers as quickly as identify of these units has yet to be decided - although it was confirmed that there will be investigations into University Hospitals Sussex and Leeds Teaching Hospitals. These could form part of the 10 or be separate to them, the government second part will undertake a system-wide look at maternity and neonatal care, bringing together lessons from past inquiries to create a national set of actions to improve care across every NHS maternity Wood, from Leeds Teaching Hospitals NHS Trust, said: "Our recent Care Quality Commission (CQC) reports have highlighted critical areas for improvement, and we've already taken significant steps to address these. "We remain committed to working closely with NHS England, the CQC, our staff and families who use our services, to ensure the highest standards of care in our maternity services." Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
BBC News
an hour ago
- BBC News
Study shows 110k people affected by domestic abuse on Merseyside
Demand for domestic abuse services on Merseyside has outstripped supply, with more than 117,000 people in the region affected, a report has found. The study, commissioned by Merseyside Police and Crime Commissioner Emily Spurrell, highlighted an "urgent" need for more stable, long-term funding in the region to support 10,000 people have received support each year from more than 20 different organisations, many of which are "operating beyond safe capacity", the report found. Spurrell said these services were "being held together by the dedication of overstretched professionals", adding there was "no quick fix" to the problem. The report produced by national charity Women's Aid and Liverpool John Moores University (LJMU) found 117,000 people, predominantly women and children , experienced domestic abuse in Merseyside each study was "a sobering but vital insight into the pressures facing our domestic abuse services", Spurrell said. 'Key gaps' The study found funding problems leading to high staff turnover at organisations which help victims, which resulted in many missing out on having a single caseworker with whom they could build were also long waiting lists, particularly for therapeutic services and gaps in provision for children and young people, and for marginalised groups and disabled people were also Aid's CEO, Farah Nazeer, said there was "an urgent need for a systematic, coordinated response that addresses key gaps in provision for children and young people as victim-survivors, Black and minoritised women and other marginalised groups".Senior Researcher for the World Health Organization Collaborating Centre for Violence Prevention Nadia Butler said the review was a "foundation for enhancing and sustaining adequate commissioning of domestic abuse services across Merseyside".Among the 20 recommendations were improved oversight and coordination of domestic abuse funding, strengthened multi-agency working, and better use of said: "While there are no quick fixes or easy solutions, this report gives us a strong foundation to work from." Listen to the best of BBC Radio Merseyside on Sounds and follow BBC Merseyside on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
